PrediCare facilitates a treatment line switch just prior to an imminent disease progression. This policy adheres to the National Comprehensive Cancer Network (NCCN) guideline, e.g., for switch maintenance therapy in non-small cell lung cancer, but in contrast to the latter modality, PrediCare enables optimization of the timing of the switch in the treatment line, and thus contributes to better patient outcomes.


PrediCare integrates weak signals from multiple tumor markers, monitored during treatment, into a combined strong signal for approaching disease progression. This “signal amplifier”, which can detect approaching disease progression and notify the oncologist, offers a new and improved use for tumor biomarkers over the present clinical practice in advanced cancer patients.